T 1025/19 (Single dose administration/BOEHRINGER INGELHEIM) 11-10-2022
Download and more information:
Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
Intervet International BV (opposition withdrawn)
Eli Lilly and Company
Basis of decision - agreement to text withdrawn by patent proprietor
Basis of decision - patent revoked by opposition division
Basis of decision - appeal dismissed
I. The appeal of the patent proprietor (appellant) lies from the opposition division's decision revoking European patent No. 2 371 385 ("the patent").
Opponent 2 is respondent to this appeal. Opponent 1 has withdrawn its opposition and has ceased to be a party to the appeal as regards substantive issues.
II. With the statement setting out the grounds of appeal, the appellant requested as a main request that the decision under appeal be set aside and that the patent be maintained as granted. Alternatively, it was requested that the patent be maintained on the basis of the set of claims of auxiliary request 1, filed
10 September 2018 in the proceedings before the opposition division, or on the basis of the set of claims of one of auxiliary requests 2 to 13, filed
3 November 2016 in the proceedings before the opposition division. Further alternatively, it was requested that the patent be maintained on the basis of the set of claims of one of auxiliary requests 14
to 21, filed 11 July 2018 in the proceedings before the opposition division. As final alternative, the patent should be maintained on the basis of one of auxiliary requests 22 to 24, filed with the statement setting out the grounds of appeal.
III. With their reply to the statement of grounds of appeal the respondent requested that the appeal be dismissed, that auxiliary request 1, filed 10 September 2018, not be admitted into the proceedings and that auxiliary requests 22 to 24 not be admitted into the proceedings. They further requested that the appellant not be permitted to file any further auxiliary requests and that the case not be remitted to the opposition division for further prosecution.
IV. The board appointed oral proceedings and, in a subsequent communication pursuant to
Article 15(1) RPBA 2020, provided its preliminary appreciation of the appeal.
V. The appellant informed the board by letter dated 8 October 2022 that they no longer approved of the text of the patent as granted, that they would not pursue any of the pending requests on file, including the auxiliary requests, and that they would not propose any other amended text. The appellant also withdrew their request for oral proceedings.
VI. The board subsequently cancelled the oral proceedings.
1. The appeal complies with Articles 106 to 108 and
Rule 99 EPC and is admissible.
2. Pursuant to the principle of party disposition established by Article 113(2) EPC, the EPO shall examine, and decide upon, the European patent only in the text submitted to it, or agreed, by the proprietor of the patent.
3. The appellant informed the board in writing that they no longer approved of the text of the patent as granted, that they would not pursue any of the pending requests on file, including the auxiliary requests, and that they would not propose any other amended text (see Section V., above).
4. According to the case law of the boards of appeal, in these circumstances the proceedings are to be terminated by a decision ordering revocation of the patent under Article 101 EPC without assessing issues relating to patentability (see decision T 73/84, OJ EPO 1985, 241, and Case Law of the Boards of Appeal of the European Patent Office, 10th edition 2022, III.B.3.3). In the case at hand, where the patent had already been revoked by the opposition division and, as correctly pointed out in decision T 454/15 (see Reasons,
point 6), cannot be revoked again, the effect of the appellant's declaration is that the appeal has to be dismissed.
For these reasons it is decided that:
The appeal is dismissed.